Partnering With Oncology: Implementing the NCODA/ADA Ototoxicity Screening Protocol
CE Information: No CE Available
Return to: Webinars
Platinum-based chemotherapy puts cancer patients at risk of hearing and balance loss. Many of these patients are treated in community oncology clinics that have no audiologist on staff.
This course will prepare audiologists to serve as oncology’s audiology partner, using the newly developed NCODA-ADA protocol. It covers the criteria for patients who will be screened, the screening protocol, and the escalation triggers, and follows the referral pathway from the abnormal screen through the audiologist’s report back to the treating oncologist. Recommended post-treatment assessments and intervals, including recommendations for amplification and vestibular therapy will also be covered.
Panelists will also discuss the practical side of the partnership, including strategies for outreach to community oncology centers, setting up primary and backup referral arrangements, handling urgent and routine referrals, and advising oncology teams on screening standards and protocols.
Join us for this insightful program and leave with the NCODA-ADA protocol in hand, ready to approach local oncology practices and become their audiology partner. Course participants will have the opportunity to register to become an ADA oncology-audiology network provider.
Learning Outcomes
By the end of this course, participants will be able to:
- Identify the patients the NCODA-ADA protocol flags for ototoxicity monitoring.
- Interpret Hearing and Balance Questionnaire responses and portable screening results against the protocol’s escalation criteria, using each patient’s own baseline.
- Describe the audiologist’s role and handoffs in the escalation pathway, from receiving the referral to sending clinically meaningful findings back to the oncology team.
- Implement a post-treatment follow-up plan that includes the 3-, 6- and 12-month audiologic assessments and appropriate rehabilitation or vestibular referrals, and ongoing life-long testing and care of the patient.
- Develop a plan to become a community oncology practice’s primary or backup audiology partner, covering referral logistics, report turnaround and communication with the practice’s Ototoxicity Prevention Team.
Additional Resources
Kayla Boyd, PharmD, BCOP is Senior Manager of Clinical Excellence at the Network for Collaborative Oncology Development & Advancement (NCODA), where she co-leads the development and refinement of several clinical resources including Positive Quality Interventions (PQIs), the Patient Treatment Calendar tool, and the forthcoming Precision Medicine Hub. She earned her PharmD from the University of South Carolina and completed PGY1 pharmacy practice and PGY2 oncology pharmacy residency training at Grady Health System in Atlanta. She then practiced as a Clinical Pharmacy Specialist in outpatient hematology/oncology with Kaiser Permanente of Georgia before joining NCODA.
Dr. Katy Mawson AuD, a cancer survivor, is a well-known advocate for ototoxic education among oncologists, ENTs and other healthcare providers. She also regularly provides audiologic education and hearing conservation strategies to patients receiving ototoxic medication. Dr. Mawson is the owner of Aspen Audiology in Portland, Oregon. She earned her Doctor of Audiology degree from Idaho State University and her Bachelor of Science in Speech Language Pathology from the University of Nevada, Reno. She is a past president of the Northwest Academy of Audiology.
Dr. Jana Brown, AuD, former owner of Allegany Hearing & Balance, earned her Doctor of Audiology degree in 2004 from the A. T. Still Arizona School of Health Sciences in Mesa, AZ. She also holds a Master of Science degree from West Virginia University. Dr. Brown currently serves as Chair of Maryland’s Board of Examiners for Audiology, Speech Language Pathology, Hearing Aid Dispensers, and Music Therapy. She is the president-elect of the Academy of Doctors of Audiology and a past president of the Maryland Academy of Audiology.